DiaMedica Gets a 15% Lift in Share Price

DiaMedica Gets a 15% Lift in Share Price
DiaMedica_Inc. (TSX-V:DMA) saw some activity in the stock today as it jumped over 15% on above average trading volume finally landing at $0.38 cents at closing. The Company is focused on developing novel treatments for vascular diseases, including stroke and metabolic and kidney dysfunction. Although there was no news out today, the Company did recently announce that the US Patent... Read More

Neovasc Gets Share Price Appreciation Despite No News

Neovasc Gets Share Price Appreciation Despite No News
Neovasc Inc. (TSX: NVC) surged over 44% by end of day, up $0.30 closing at $0.90 on above average volume of 796,800 shares being traded. No recent news could be attributed to the share price appreciation other than completing the Annual Shareholders Meeting on June 15th where all six Directors had been re-elected. Neovasc is a specialty medical device company... Read More

Covalon Lands Distribution Deal With Medline

Covalon Lands Distribution Deal With Medline
Covalon Technologies Ltd. (TSXV: COV) share price received a boost after announcing a distribution agreement with Medline Industries Inc., the largest privately held medical distributor in the United States. Medline will be distributing Covalon-branded products lines into its extensive United States customer base. Shares of Covalon were up 37% reaching a day high of $1.49 on above average volume and... Read More

Dehaier Medical Receives US$20 Million Investment

Dehaier Medical Receives US$20 Million Investment
Dehaier Medical Systems Ltd. (NASDAQ: DHRM) receives US$20 million to expand their wearable medical device business and to launch other new smart wearable devices and mobile medical solutions over the next few years. The Company entered into a definitive securities purchase agreement with Hangzhou Liaison Interactive Information Technology Co. Ltd., a publicly listed company on the Shenzhen Stock Exchange (Symbol:... Read More

Aytu BioScience Enters $2 Billion Testosterone Replacement Market

Aytu BioScience Enters $2 Billion Testosterone Replacement Market
Aytu_BioScience, Inc. (OTCQX: AYTU) is paying $2 million upfront and purchasing $2 million of Acerus Pharmaceuticals Corporation (TSX: ASP) common stock for an exclusive license agreement for the U.S. commercial rights to Natesto® Nasal Gel. Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA) as a replacement therapy for men... Read More

Arch Therapeutics, Inc. Breaking 52 Week High

Arch Therapeutics, Inc. Breaking 52 Week High
Arch Therapeutics, Inc. (OTCQB: ARTH), developer of the AC5 Surgical Hemostatic Device, has garnered some interest by retail investors as the stock broke through its 52 week high of $0.45 with above average volume. Arch announced last month they obtained favorable results from a broad panel of preclinical biocompatibility tests that were performed on AC5, which is required prior to... Read More

Protea Biosciences Group Stock On The Move

Protea Biosciences Group Stock On The Move
Protea Biosciences Group, Inc. (OTCQB:PRGB) stock surged up 50% to $0.21 cents on above average volume late in the trading day. No new news was issued since the Company reported total revenue of $2,003,286 on March 16, 2016, an increase of 13% over FY2014 revenue of $1,768,312. Protea Biosciences provides innovative bioanalytical solutions to the pharmaceutical and life science industries... Read More

International Stem Cell Corporation to Raise $6.3 Million

International Stem Cell Corporation to Raise $6.3 Million
  International Stem Cell Corporation (OTCQB: ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human... Read More